

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

8

Complete if Known

Application Number	10/785,374
Filing Date	2/24/2004
First Named Inventor	Summar et al.
Art Unit	1634
Examiner Name	Diana B. Johannsen

Attorney Docket Number 1242/58 CIP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1	US-4,196,265	04-01-1980	Koprowski et al.		
2	US-4,458,066	07-03-1984	Caruther et al.		
3	US-4,554,101	11-19-1985	Hopp		
4	US-4,683,195	07-28-1987	Mullis et al.		
5	US-4,683,202	07-28-1987	Mullis		
6	US-4,736,866	04-12-1988	Leder et al.		
7	US-4,769,331	09-06-1988	Roziman et al.		
8	US-4,965,188	10-23-1990	Mullis et al.		
9	US-4,996,236	02-26-1991	Nakamura et al.		
10	US-5,162,215	11-10-1992	Bosselman et al.		
11	US-5,217,997	06-08-1993	Levere		
12	US-5,279,833	01-18-1994	Rose		
13	US-5,286,634	02-15-1994	Stadler et al.		
14	US-5,399,346	03-21-1995	Anderson et al.		
15	US-5,489,742	02-06-1996	Hammer et al.		
16	US-5,550,316	08-27-1996	Mintz		
17	US-5,550,024	08-27-1996	Rothschild		
18	US-5,573,933	11-12-1996	Seamark et al.		
19	US-5,614,396	03-25-1997	Bradley et al.		
20	US-5,625,125	04-29-1997	Bennett et al.		
21	US-5,641,484	06-24-1997	Hung et al.		
22	US-5,643,567	07-01-1997	Hung et al.		
23	US-5,646,008	07-08-1997	Thompson et al.		
24	US-5,648,061	07-15-1997	Bernstein et al.		
25	US-5,651,964	07-29-1997	Hung et al.		
26	US-5,741,957	04-21-1998	Deboer et al.		

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/785,374
				Filing Date	2/24/2004
				First Named Inventor	Summar et al.
				Art Unit	1634
				Examiner Name	Diana B. Johannsen
(Use as many sheets as necessary)					
Sheet	2	of	8	Attorney Docket Number	1242/58 CJP

U.S. PATENT DOCUMENTS

Cited Patent Documents				
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	27	US-6,343,382	02-05-2002	Sciglia
	28	US-6,346,382	02-12-2002	Summar et al.
	29	US-6,358,536	03-19-2002	Thomas
	30	US-6,743,823	06-01-2004	Summar et al.
	31	US-2006/0194728	08-31-2006	Killian et al.
	32	US-2007/0026448	02-01-2007	Ramanathan et al.
	33	US-2007/0184554	08-09-2007	Teuscher et al.
	34	US-2008/234379	09-25-2008	Summar et al.
	35	US-2009-0197964	08-06-2009	Summar et al.
	36	US-2009-0312423	12-17-2009	Summar et al.

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be given (including by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /D.B./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/785,374		
(Use as many sheets as necessary)		Filing Date	2/24/2004		
Sheet	3	First Named Inventor	Summar et al.		
		Art Unit	1634		
		Examiner Name	Diana B. Johannsen		
		Attorney Docket Number 1242/58 CIP			

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	38	Ahrens et al., "Consensus statement from a Conference for the Management of Patients With Urea Cycle Disorders," Supplement to the Journal of Pediatrics, Vol. 138, No. 1, pgs. S1-S5 (January 2001).				
	39	Ananthkrishnan et al., "L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets," Am. J. Physiol. Lung Cell. Mol. Physiol., Vol. 297, pgs. L506-L511 (2009).				
	40	Ballard et al., "Inhaled nitric oxide in preterm infants undergoing mechanical ventilation," N. Engl. J. Med., Vol. 355, No. 4, pgs. 343-353 (2006).				
	41	Barr et al., "Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: Potential therapy for postoperative pulmonary hypertension," The Journal of Thoracic and Cardiovascular Surgery, Vol. 134, No. 2, pgs. 319-326 (August 2007).				
	42	Barsotti, "Measurement of ammonia in blood," The Journal Of Pediatrics, Vol. 138, pgs. S11-S20 (January 2001).				
	43	Batista da Costa, Jr. et al., "Surgical treatment of intracranial aneurysms: six-year experience in Belo Horizonte, MG, Brazil," Arq Neuro-Psiquiatr (Sao Paulo), Vol. 62, pgs. 245-249 (2004).				
	44	Batshaw et al., "Alternative pathway therapy for urea cycle disorders: Twenty years later," J. Pediatr., Vol. 138, pgs. S46-S55 (2001).				
	45	Berkenbosch et al., "Decreased synthesis and vasodilation to nitric oxide in piglets with hypoxia-induced pulmonary hypertension," Am. J. Physiol. Lung Cell. Mol. Physiol., Vol. 278, pgs. L276-L283 (2000).				
	46	Coude et al., "Inhibition of ureagenesis by valproate in rat hepatocytes. Role of N-acetylglutamate and acetyl-CoA," Biochem. J., Vol. 216, pgs. 233-236 (1983).				
	47	Dimopoulos et al., "High Incidence of Neuroendocrine Dysfunction in Long-Term Survivors of Aneurysmal Subarachnoid Hemorrhage," Stroke, Vol. 35, pgs. 2884-2889 (2004).				
	48	Flett et al., "Aneurysmal Subarachnoid Hemorrhage: Management Strategies and Clinical Outcomes in a Regional Neuroscience Center," AJNR Am. J. Neuroradiol., Vol. 26, pgs. 367-372 (2005).				
	49	Genbank Accession No. AB005003				
	50	Genbank Accession No. AJ0005315				
	51	Genbank Accession No. BAA21088				
	52	Genbank Accession No. M11710				
	53	Genbank Accession No. M12318				

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/785,374
				Filing Date	2/24/2004
				First Named Inventor	Summar et al.
				Art Unit	1634
				Examiner Name	Diana B. Johannsen
Sheet	4	of	8	3Attorney Docket Number	1242/58 CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
54		Genbank Accession No. M12319	
55		Genbank Accession No. M12320	
56		Genbank Accession No. M12321	
57		Genbank Accession No. M12322	
58		Genbank Accession No. M12323	
59		Genbank Accession No. M12324	
60		Genbank Accession No. M12325	
61		Genbank Accession No. M12326	
62		Genbank Accession No. M12327	
63		Genbank Accession No. M12328	
64		Genbank Accession No. M12335	
65		Genbank Accession No. M27174	
66		Genbank Accession No. P02065	
67		Genbank Accession No. P07250	
68		Genbank Accession No. X67573	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation does not require a (continued). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.91. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

8

Complete If Known

Application Number	10/785,374
Filing Date	2/24/2004
First Named Inventor	Summar et al.
Art Unit	1634
Examiner Name	Diana B. Johannsen

Attorney Docket Number 1242/58 CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	69	Horiuchi et al., "Sex-Related Differences in Patients Treated Surgically for Aneurysmal Subarachnoid Hemorrhage," <i>Neurol. Med. Chir. (Tokyo)</i> , Vol. 46, pgs. 328-332 (2006).	
	70	Interview Summary corresponding to U.S. Patent Application Serial No. 09/585,077 dated November 4, 2004.	
	71	Jobe et al., "Bronchopulmonary Dysplasia," <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 163, pgs. 1723-1729 (2001).	
	72	Kinouchi et al., "Prevention of Symptomatic Vasospasm After Aneurysmal Subarachnoid Hemorrhage by Intraoperative Cisternal Fibrinolysis Using Tissue-Type Plasminogen Activator Combined with Continuous Cisternal Drainage," <i>Neurol. Med. Chir. (Tokyo)</i> , Vol.	
	73	Kivisaari et al., "MR Imaging After Aneurysmal Subarachnoid Hemorrhage and Surgery: A Long-term Follow-up Study," <i>AJNR Am. J. Neuroradiol.</i> , Vol. 22, pgs. 1143-1148 (June/July 2001).	
	74	Leonard, J., "The nutritional management of urea cycle disorders," <i>The Journal of Pediatrics</i> , Vol. 138, No. 1, pgs. S40-S45 (2001).	
	75	Notice of Allowance corresponding to U.S. Patent Application Serial No. 09/323,472 (Patent No. 6,346,382) dated August 9, 2001.	
	76	Notice of Allowance corresponding to U.S. Patent Application Serial No. 09/585,077 dated October 8, 2003.	
	77	Notification of Transmittal of International Search Report or the Declaration corresponding to International Application No. PCT/US00/15079 dated August 22, 2000.	
	78	Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration corresponding to International Application No. PCT/US 09/32824 dated April 21, 2009.	
	79	Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration corresponding to International Application No. PCT/US 09/32826 dated March 25, 2009.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

8

Complete If Known

Application Number	10/785,374
Filing Date	2/24/2004
First Named Inventor	Summar et al.
Art Unit	1634
Examiner Name	Diana B. Johannsen

Attorney Docket Number 1242/58 CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	80	Office Action corresponding to European Patent Application No. 06 005 642.1 – 2403 dated November 12, 2010.	
	81	Office Action corresponding to U.S. Patent Application Serial No. 09/989,956 dated October 18, 2006.	
	82	Office Action corresponding to U.S. Patent Application Serial No. 09/989,956 dated January 30, 2006.	
	83	Office Action corresponding to U.S. Patent Application Serial No. 09/989,956 dated July 1, 2004.	
	84	Office Action corresponding to U.S. Patent Application Serial No. 09/323,472 (Patent No. 6,346,382) dated December 20, 2000.	
	85	Office Action corresponding to U.S. Patent Application Serial No. 09/585,077 dated July 3, 2002.	
	86	Office Action corresponding to U.S. Patent Application Serial No. 12/122,117 dated April 21, 2010.	
	87	Office Action corresponding to U.S. Patent Application Serial No. 12/122,117 dated July 22, 2010.	
	88	Office Action corresponding to U.S. Patent Application Serial No. 12/364,078 dated October 21, 2010.	
	89	Office Action corresponding to U.S. Patent Application Serial No. 12/364,078 dated March 4, 2010.	
	90	Olsvik et al., "A nested PCR followed by magnetic separation of amplified fragments for detection of <i>Escherichia coli</i> Shiga-like toxin genes," Molecular and Cellular Probes, Vol. 5, pgs. 429-435 (December 1991).	
	91	Rabinstein et al., "Patterns of Cerebral Infarction in Aneurysmal Subarachnoid Hemorrhage," Stroke, Vol. 36, pgs. 992-997 (2005).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This burden will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

8

Complete if Known

Application Number	10/785,374
Filing Date	2/24/2004
First Named Inventor	Summar et al.
Art Unit	1634
Examiner Name	Diana B. Johannsen
Attorney Docket Number	1242/58 CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	92	Ravnik et al., "Long-term Cognitive Deficits in Patients with Good Outcomes after Aneurysmal Subarachnoid Hemorrhage from Anterior Communicating Artery," Croat. Med. J., Vol. 47, pgs. 253-263 (2006).	
	93	Rubenfeld et al., "Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines," Annals of Internal Medicine, Vol. 125, pgs. 625-633 (1996).	
	94	Rubio and Grisolía, "Human Carbamoylphosphate Synthetase I," Enzyme, Vol. 26, pgs. 233-239 (1981).	
	95	Ryan, R. M., "A new look at bronchopulmonary dysplasia classification," J. Perinatology, Vol. 26, pgs. 207-209 (2006).	
	96	Saiki, R.K., "Amplification of Genomic DNA," Chapter 2 in PCR Protocols: A Guide to Methods and Applications, Innis, M.A. et al, eds., Academic Press, Inc., San Diego, pgs 13-21 (1990).	
	97	Sakowitz et al., "Relation of Cerebral Energy Metabolism and Extracellular Nitrite and Nitrate Concentrations in Patients after Aneurysmal Subarachnoid Hemorrhage," Journal of Cerebral Blood Flow and Metabolism, Vol. 21, pgs. 1067-1076 (2001).	
	98	Schreiber et al. "Inhaled nitric oxide in premature infants with respiratory distress syndrome", New England J. Med., Vol. 349, pgs. 2099-2107 (2003).	
	99	Sercombe et al., "Cerebrovascular Inflammation Following Subarachnoid Hemorrhage," Jpn. J. Pharmacol., Vol. 88, pgs. 227-249 (2002).	
	100	Singh et al., "Nutritional Management of Urea Cycle Disorders," Crit. Care Clin., Vol. 21, pgs. S27-S35, (2005).	
	101	Smith et al., "Nitric oxide precursors and congenital heart surgery: A randomized controlled trial of oral citrulline," The Journal of Thoracic and Cardiovascular Surgery, Vol. 132, No. 1, pgs. 58-65 (July 2006).	
	102	Smith et al., "Urea Cycle Disorders: Clinical Presentation Outside the Newborn Period," Crit Care Clin, Vol. 21, pgs. S9-S17 (2005).	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

8

of

8

Application Number

10/785,374

Filing Date

2/24/2004

First Named Inventor

Summar et al.

Art Unit

1634

Examiner Name

Diana B. Johannsen

Attorney Docket Number

1242/58 CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	103	Suarez et al., "Aneurysmal Subarachnoid Hemorrhage," N. Engl. J. Med., Vol. 354, pgs. 387-396 (2006).	
	104	Summar and Tuchman, "Proceedings of a Consensus Conference for the Management of Patients with Urea Cycle Disorders," J. Pediatr., Vol. 138, pgs. S6-S10 (2001).	
	105	Summar, M., "Current strategies for the management of neonatal urea cycle disorders," J. Pediatr., Vol. 138, pgs. S30-S39 (2001).	
	106	Takiguchi, "Transcriptional regulation of genes for ornithine cycle enzymes," Biochem J., Vol. 312, pgs. 649-659 (1995).	
	107	Thorell et al., "Optical Coherence Tomography: A New Method to Assess Aneurysm Healing," J. Neurosurg., Vol. 102, No. 2, pgs. 348-354 (2005).	
	108	van der Schaaf et al., "New Detected Aneurysms on Follow-Up Screening in Patients with Previously Clipped Intracranial Aneurysms: Comparison with DSA or CTA at the Time of SAH," Stroke, Vol. 36, pgs. 1753-1758 (2005).	
	109	Wong et al., "Use of Phenytoin and Other Anticonvulsant Prophylaxis in Patients with Aneurysmal Subarachnoid Hemorrhage Response," Stroke, Vol. 36, pg. 2532 (2005).	

Examiner Signature	/Diana B. Johannsen/	Date Considered	09/22/2011
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.